Clinical Trials on Carcinoma of Male Breast

Total 6919 results

National Taiwan University Hospital

Unknown

Sense of Hope Alleviates Fatigue in Breast Cancer Survivors

Carcinoma of Male Breast

Taiwan
University of Arizona
National Cancer Institute (NCI)

Completed

Paclitaxel and Bavituximab in Treating Patients With HER2-Negative Metastatic Breast Cancer

Male Breast Cancer | Stage IV Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Human Epidermal Growth Factor 2 Negative Carcinoma of Breast

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer

Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Ductal Breast Carcinoma in Situ | Lobular Breast Carcinoma in Situ

United States
University of Arizona
National Cancer Institute (NCI); GlaxoSmithKline

Terminated

Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer

Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-positive Breast Cancer | Human Epidermal Growth Factor 2 Negative Carcinoma of Breast

United States
Methodist Health System

Recruiting

Demographics, Characteristics and Outcomes of Male Breast Cancer Patients at Methodist Health System

Ductal Carcinoma in Situ | Invasive Lobular Breast Carcinoma

United States
Nuvation Bio Inc.

Terminated

Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors

Glioma | Breast Cancer | Glioblastoma | Advanced Breast Cancer | Prostate Cancer | Metastatic Breast Cancer | Recurrent Glioblastoma | Breast Carcinoma | Castration-resistant Prostate Cancer | Prostate Neoplasm | Cancer of the Prostate | Prostatic Cancer | Glioma, Malignant | Cancer of Breast | Malignant Tumor of Breast and other conditions

United States
Case Comprehensive Cancer Center

Withdrawn

Breast-Conserving Surgery Followed by Radiation Therapy With MRI-Detected Stage I or Stage II Breast Cancer

Stage I Breast Cancer | HER2-positive Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast Cancer | HER2-negative Breast... and other conditions

United States
National Cancer Institute (NCI)

Completed

Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast Cancer

Recurrent Breast Carcinoma | Male Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7

United States
Mayo Clinic

Recruiting

Collection of Specimens and Clinical Data for Patients With Recurrent or Metastatic Breast Cancer or Male Breast Cancer

Breast Carcinoma | Recurrent Breast Carcinoma | Metastatic Breast Carcinoma

United States
University of Chicago

Active, not recruiting

Hypofractionated Image Guided Radiation Therapy in Treating Patients With Stage IV Breast Cancer

Lung Metastases | Liver Metastases | Male Breast Cancer | Stage IV Breast Cancer | Recurrent Breast Cancer | Invasive Lobular Breast Carcinoma | Central Nervous System Metastases | Tumors Metastatic to Brain | Lobular Breast Carcinoma in Situ | Invasive Ductal Breast Carcinoma | Medullary Ductal Breast Carcinoma... and other conditions

United States
National Cancer Institute (NCI)

Completed

Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast Cancer

Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Male Breast Carcinoma | Inflammatory Breast Carcinoma | Adult Solid Neoplasm

United States
Celltrion
Nippon Kayaku Co., Ltd.

Completed

Efficacy and Safety Evaluating Study of CT-P6 in Her2 Positive Early Breast Cancer

HER2-positive Carcinoma of Breast

Italy, South Africa, Mexico, Japan, Taiwan, Russian Federation, Philippines, Hungary, Romania, Spain, Bosnia and Herzegovina, India, Peru, Ukraine, Latvia, Argentina, Georgia, Belarus, Chile, France, Poland, Portugal
Jose Pablo Leone
Eli Lilly and Company; Translational Breast Cancer Research Consortium (TBCRC)

Recruiting

ETHAN - ET for Male BC

Male Breast Cancer | Hormone Receptor-positive Breast Cancer | Hormone Receptor Negative Breast Carcinoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer

Recurrent Breast Carcinoma | Triple-Negative Breast Carcinoma | Male Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Stage IIIC Breast Cancer AJCC v7

United States
Shanghai Jiao Tong University School of Medicine
Shanghai 10th People's Hospital; China-Japan Union Hospital, Jilin University; Ganzhou City People's Hospital

Recruiting

A Randomized Trial of Chemotherapy in Surgical Patients With Infiltrating Ductal Carcinoma of Breast (COC-IDCB)

Breast Cancer

China
National Cancer Institute (NCI)

Completed

Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery

Stage IV Breast Cancer | Recurrent Breast Carcinoma | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma | Male Breast Carcinoma | Adult Solid Neoplasm

United States
National Cancer Institute (NCI)

Terminated

Pazopanib in Treating Patients With Newly Diagnosed or Locally and/or Regionally Recurrent Breast Cancer That Can Be Removed By Surgery

Recurrent Breast Carcinoma | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Male Breast Carcinoma

United States
National Cancer Institute (NCI)

Completed

Study of Docosahexaenoic Acid (DHA) in Triple Negative Breast Cancer Survivors

Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Invasive Breast Carcinoma | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Lobular Breast Carcinoma In Situ | Ductal Breast Carcinoma In Situ | Paget Disease of the Breast | Benign Breast Neoplasm

United States
National Cancer Institute (NCI)

Completed

Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer

Recurrent Breast Carcinoma | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma | Male Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7

United States
National Cancer Institute (NCI)

Completed

Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Stage IV Breast Cancer | Recurrent Breast Carcinoma | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma | Male Breast Carcinoma | Adult Solid Neoplasm

United States
Guangdong Academy of Medical Sciences
Guangzhou First People's Hospital; Guangzhou General Hospital of Guangzhou... and other collaborators

Unknown

Compare the Outcomes of XT and XEC Adjuvant Chemotherapy in HER2-negative Luminal B Breast Cancer Patients

Human Epidermal Growth Factor 2 Negative Carcinoma of Breast

China
Fondazione IRCCS Istituto Nazionale dei Tumori,...

Completed

Ten Years Results of a Score System to Address Adjuvant Therapies After Breast Conserving Surgery for Ductal Carcinoma in Situ of the Breast (DCIS)

Carcinoma Breast

Italy
Eli Lilly and Company

Completed

Pemetrexed as the First Treatment in Advanced or Metastatic Breast Cancer

Breast Cancer | Breast Neoplasms, Male | Carcinoma, Ductal

United States
Qingdao Central Hospital

Completed

Radiotherapy Alternates Human Epidermal Growth Factor 2 (Her2) Expression in Human Breast Cancer

Human Epidermal Growth Factor 2 Negative Carcinoma of Breast

China
Istituto Scientifico Romagnolo per lo Studio e...

Completed

Myocet + Cyclophosphamide + Metformin Vs Myocet + Cyclophosphamide in 1st Line Treatment of HER2 Neg. Metastatic Breast Cancer Patients (MYME)

Human Epidermal Growth Factor 2 Negative Carcinoma of Breast

Italy
National Cancer Institute (NCI)

Terminated

RO4929097 And Exemestane in Treating Pre- and Postmenopausal Patients With Advanced or Metastatic Breast Cancer

Stage IV Breast Cancer | Recurrent Breast Carcinoma | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor Positive | HER2/Neu Negative | Male Breast Carcinoma

United States
Innocrin Pharmaceutical

Completed

CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448) (CLARITY-01)

Breast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the Breast

United States
National Cancer Institute (NCI)

Completed

Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Tamoxifen

Stage IV Breast Cancer | Recurrent Breast Carcinoma | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor Positive | Progesterone Receptor Positive | Male Breast Carcinoma

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Terminated

Gefitinib Followed By Surgery in Treating Women With Ductal Carcinoma In Situ of the Breast

Breast Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery

Triple-Negative Breast Carcinoma | Male Breast Carcinoma | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7 | Stage IIIA Breast Cancer AJCC v7

United States
University of Southern California

Terminated

Targeted Intra-Operative Radiotherapy for the Management of Ductal Carcinoma In-Situ of the Breast

Breast Cancer

United States
First Hospital of China Medical University
Jilin Provincial Tumor Hospital; The First Hospital of Jilin University; Second... and other collaborators

Unknown

Effect of Endocrine Therapy Duration on Clinical Outcome of Patients With HR+ Intraductal Carcinoma of the Breast

Breast Cancer

China
Dana-Farber Cancer Institute
Massachusetts General Hospital; Beth Israel Deaconess Medical Center; Brigham...

Active, not recruiting

Wide Excision Alone as Treatment for Ductal Carcinoma in Situ of The Breast

Ductal Carcinoma in Situ of the Breast

United States
McMaster University
St. Joseph's Healthcare Hamilton; Hamilton Health Sciences Corporation

Unknown

Axillary Reverse Mapping (ARM) Technique (ARM)

Invasive Breast Cancer | Ductal Carcinoma in Situ of the Breast

Canada
Memorial Sloan Kettering Cancer Center
National Institutes of Health (NIH)

Recruiting

Testing a New Imaging Agent to Identify Cancer

HER2-positive Metastatic Breast Cancer | HER-2 Protein Overexpression | HER-2 Positive Malignant Carcinoma of Breast

United States
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

A Study to Evaluate the Efficacy and Safety of Oral Navelbine in Female Patients With HER2-Negative Metastatic Breast Cancer

Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Washington University School of Medicine
Pfizer

Completed

Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer

Breast Cancer | Breast Carcinoma | Cancer of Breast | Malignant Tumor of Breast

United States
Nuvation Bio Inc.

Withdrawn

Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC

Breast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Breast Carcinoma | Cancer of Breast | Malignant Tumor of Breast | Breast Tumor | Cancer of the Breast

United States
Karolinska University Hospital

Active, not recruiting

Therapeutic Dose Monitoring (TDM) of Tamoxifen

Breast Cancer | Breast Tumors | Breast Carcinoma | Cancer of Breast | Malignant Neoplasm of Breast

Sweden
Indiana University
National Cancer Institute (NCI); Indiana University Health; Eskenazi Health

Active, not recruiting

Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors

Breast Cancer | Anxiety | Breast Neoplasm | Breast Carcinoma | Fear | Cancer of Breast | Malignant Tumor of Breast | Malignant Neoplasm of Breast | Mammary Cancer | Mammary Neoplasms, Human | Human Mammary Carcinoma | Mammary Carcinoma, Human

United States
National Cancer Institute (NCI)

Completed

Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Breast Carcinoma | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma | Male Breast Carcinoma | Stage IV Breast Cancer AJCC...

United States
H. Lee Moffitt Cancer Center and Research Institute
United States Department of Defense

Active, not recruiting

HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer

Breast Cancer | Breast Cancer, Male | HER2-positive Breast Cancer | Invasive Breast Cancer | Stage II Breast Cancer | Breast Cancer Female | HER2 Positive Breast Carcinoma | Stage III Breast Cancer

United States
Emory University

Completed

Evaluating and Comparing Two Surgical Methods for Treatment of Early Stage Breast Cancer

Breast Cancer | Breast Neoplasms | Breast Tumors | Neoplasms, Breast | Cancer of Breast | Cancer of the Breast | Human Mammary Carcinoma

United States
Danish Breast Cancer Cooperative Group
Danish Cancer Society

Active, not recruiting

Hypofractionated Versus Standard Fractionated Whole Breast Irradiation to Node-negative Breast Cancer Patients

Breast Cancer | Carcinoma in Situ of the Breast

Denmark
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Completed

Oxybutynin Chloride in Managing Hot Flashes

Hot Flashes | Breast Carcinoma | Lobular Breast Carcinoma In Situ | Ductal Breast Carcinoma In Situ | No Evidence of Disease

United States
H. Lee Moffitt Cancer Center and Research Institute

Terminated

Immune Response and Potential Booster for Patients Who Have Received HER2-pulsed DC1

Breast Cancer | Breast Cancer, Male | HER2-positive Breast Cancer | HER-2 Gene Amplification | Breast Cancer Female | HER2 Positive Breast Carcinoma | HER-2 Protein Overexpression

United States
National Cancer Institute (NCI)

Completed

Letrozole in Preventing Breast Cancer in Healthy Postmenopausal Women at High Risk for Breast Cancer

Healthy, no Evidence of Disease | Lobular Breast Carcinoma in Situ

United States
Thomas Jefferson University

Recruiting

Prospective Breast Cancer Biospecimen Collection

Breast Cancer | Invasive Breast Cancer | Carcinoma in Situ of the Breast

United States
RenJi Hospital

Recruiting

Addition of Cisplatin to Adjuvant Chemotherapy for Early Stage Breast Cancer in High-Risk Women

Tubular Breast Cancer | Mucinous Breast Cancer | Invasive Duct Carcinoma of Breast

China
Integro Theranostics

Recruiting

LS301-IT in Partial Mastectomy and Sentinel Lymph Node Biopsy (SLNB) for DCIS or Stage I-II Primary Invasive Breast Cancer

Breast Cancer | DCIS | Invasive Duct Carcinoma of Breast

United States

Clinical Trials on Carcinoma of Male Breast

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jamaica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations